In 2020, the American Society of Clinical Oncology (ASCO) guidelines suggested the combination of ICI atezolizumab with the anti-vascular endothelial growth factor (VEGF) drug bevacizumab as a first-line systemic treatment for advanced unresectable HCC patients [121]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.